CN111575380B - 多基因检测用的探针库、杂交试剂盒和多基因检测的方法 - Google Patents
多基因检测用的探针库、杂交试剂盒和多基因检测的方法 Download PDFInfo
- Publication number
- CN111575380B CN111575380B CN202010472375.3A CN202010472375A CN111575380B CN 111575380 B CN111575380 B CN 111575380B CN 202010472375 A CN202010472375 A CN 202010472375A CN 111575380 B CN111575380 B CN 111575380B
- Authority
- CN
- China
- Prior art keywords
- genes
- seq
- probe
- dna
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000523 sample Substances 0.000 title claims abstract description 130
- 238000001514 detection method Methods 0.000 title claims abstract description 23
- 238000009396 hybridization Methods 0.000 title claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 99
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 55
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 230000007614 genetic variation Effects 0.000 claims abstract description 17
- 108700005077 Viral Genes Proteins 0.000 claims abstract description 13
- 108091092878 Microsatellite Proteins 0.000 claims abstract description 12
- 238000009169 immunotherapy Methods 0.000 claims abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 9
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims abstract description 9
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 9
- 108020004414 DNA Proteins 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 23
- 238000012163 sequencing technique Methods 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 11
- 208000032818 Microsatellite Instability Diseases 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims description 3
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 claims description 3
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 claims description 3
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 claims description 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 2
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 claims description 2
- 102100022477 DNA repair protein complementing XP-C cells Human genes 0.000 claims description 2
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 claims description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 2
- 102100038595 Estrogen receptor Human genes 0.000 claims description 2
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 claims description 2
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 claims description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 2
- 102100030708 GTPase KRas Human genes 0.000 claims description 2
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims description 2
- 101000896586 Homo sapiens Cytochrome P450 2D6 Proteins 0.000 claims description 2
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 claims description 2
- 101000618535 Homo sapiens DNA repair protein complementing XP-C cells Proteins 0.000 claims description 2
- 101000902632 Homo sapiens Dihydropyrimidine dehydrogenase [NADP(+)] Proteins 0.000 claims description 2
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 claims description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 2
- 101000995200 Homo sapiens Neurabin-2 Proteins 0.000 claims description 2
- 101000896576 Homo sapiens Putative cytochrome P450 2D7 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101001074727 Homo sapiens Ribonucleoside-diphosphate reductase large subunit Proteins 0.000 claims description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 2
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 claims description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 2
- 102100034437 Neurabin-2 Human genes 0.000 claims description 2
- 108010065129 Patched-1 Receptor Proteins 0.000 claims description 2
- 102000012850 Patched-1 Receptor Human genes 0.000 claims description 2
- 102100021702 Putative cytochrome P450 2D7 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 claims description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 2
- 102100038618 Thymidylate synthase Human genes 0.000 claims description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 claims 1
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000002626 targeted therapy Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004745 cervical carcinogenesis Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- -1 point mutation Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/173—Modifications characterised by incorporating a polynucleotide run, e.g. polyAs, polyTs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/191—Modifications characterised by incorporating an adaptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010472375.3A CN111575380B (zh) | 2018-12-24 | 2018-12-24 | 多基因检测用的探针库、杂交试剂盒和多基因检测的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010472375.3A CN111575380B (zh) | 2018-12-24 | 2018-12-24 | 多基因检测用的探针库、杂交试剂盒和多基因检测的方法 |
CN201811584036.3A CN109609635B (zh) | 2018-12-24 | 2018-12-24 | 多基因富集的探针库及与多种肿瘤治疗相关的多个基因的检测方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811584036.3A Division CN109609635B (zh) | 2018-12-24 | 2018-12-24 | 多基因富集的探针库及与多种肿瘤治疗相关的多个基因的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111575380A CN111575380A (zh) | 2020-08-25 |
CN111575380B true CN111575380B (zh) | 2021-04-02 |
Family
ID=66011766
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811584036.3A Active CN109609635B (zh) | 2018-12-24 | 2018-12-24 | 多基因富集的探针库及与多种肿瘤治疗相关的多个基因的检测方法 |
CN202010031664.XA Active CN111187810B (zh) | 2018-12-24 | 2018-12-24 | 非诊断治疗目的的多个肿瘤相关基因的检测方法 |
CN202010472375.3A Active CN111575380B (zh) | 2018-12-24 | 2018-12-24 | 多基因检测用的探针库、杂交试剂盒和多基因检测的方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811584036.3A Active CN109609635B (zh) | 2018-12-24 | 2018-12-24 | 多基因富集的探针库及与多种肿瘤治疗相关的多个基因的检测方法 |
CN202010031664.XA Active CN111187810B (zh) | 2018-12-24 | 2018-12-24 | 非诊断治疗目的的多个肿瘤相关基因的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN109609635B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111370059A (zh) * | 2020-03-05 | 2020-07-03 | 上海市肺科医院(上海市职业病防治院) | 一种肿瘤突变负荷的预测系统及方法 |
CN111662981A (zh) * | 2020-06-09 | 2020-09-15 | 俊兮生物科技(上海)有限公司 | 一种基于二代测序探针捕获方法的癌症的基因检测试剂盒 |
CN112176058A (zh) * | 2020-09-25 | 2021-01-05 | 深圳市海普洛斯生物科技有限公司 | 检测肿瘤生物标志物的探针库、方法及试剂盒 |
CN114317751A (zh) * | 2021-12-30 | 2022-04-12 | 深圳市海普洛斯生物科技有限公司 | 检测泌尿系统肿瘤标志物的探针库及其基因芯片与试剂盒 |
CN114317752A (zh) * | 2021-12-30 | 2022-04-12 | 深圳市海普洛斯生物科技有限公司 | 一种前列腺肿瘤检测探针库及其基因芯片与试剂盒 |
CN115011594B (zh) * | 2022-05-16 | 2023-10-20 | 纳昂达(南京)生物科技有限公司 | 一种用于检测hpv的液相杂交捕获探针、应用及其试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106906297A (zh) * | 2017-04-13 | 2017-06-30 | 常州桐树生物科技有限公司 | 检测肿瘤耐药性变异的检测剂 |
CN107513565A (zh) * | 2017-09-06 | 2017-12-26 | 南京世和基因生物技术有限公司 | 一种微卫星不稳定位点组合、检测试剂盒及其应用 |
CN107735500A (zh) * | 2015-04-20 | 2018-02-23 | 宾夕法尼亚大学董事会 | 用于检测乳腺癌的宏基因组组合物和方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102965428A (zh) * | 2011-09-30 | 2013-03-13 | 康旭基因技术(北京)有限公司 | 一种检验鉴别遗传性心肌肥厚相关基因突变的试剂盒 |
CN105297145B (zh) * | 2015-11-06 | 2019-03-08 | 艾吉泰康生物科技(北京)有限公司 | 一种制备基因dna探针文库的方法和试剂盒 |
CN108866154B (zh) * | 2017-05-15 | 2021-11-16 | 深圳华大基因股份有限公司 | 基于长片段dna捕获和三代测序的无创产前单体型构建方法 |
CN107502654A (zh) * | 2017-06-15 | 2017-12-22 | 至本医疗科技(上海)有限公司 | 用于实体瘤靶向用药指导的多基因富集和检测方法 |
CN107475375B (zh) * | 2017-08-01 | 2018-08-24 | 南京世和基因生物技术有限公司 | 一种用于与微卫星不稳定性相关微卫星位点进行杂交的dna探针库、检测方法和试剂盒 |
CN108676865A (zh) * | 2018-04-08 | 2018-10-19 | 复旦大学附属眼耳鼻喉科医院 | 一种儿童青光眼相关基因芯片及其制备方法和应用 |
-
2018
- 2018-12-24 CN CN201811584036.3A patent/CN109609635B/zh active Active
- 2018-12-24 CN CN202010031664.XA patent/CN111187810B/zh active Active
- 2018-12-24 CN CN202010472375.3A patent/CN111575380B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107735500A (zh) * | 2015-04-20 | 2018-02-23 | 宾夕法尼亚大学董事会 | 用于检测乳腺癌的宏基因组组合物和方法 |
CN106906297A (zh) * | 2017-04-13 | 2017-06-30 | 常州桐树生物科技有限公司 | 检测肿瘤耐药性变异的检测剂 |
CN107513565A (zh) * | 2017-09-06 | 2017-12-26 | 南京世和基因生物技术有限公司 | 一种微卫星不稳定位点组合、检测试剂盒及其应用 |
Non-Patent Citations (2)
Title |
---|
clinical application of cancer genomic profiling assay to guide precision medicine decisions;Cheryl Eifert等;《PER.MED.》;20170526;309-325 * |
生物标志物在胃肠肿瘤治疗中的应用现状及前景;刘静等;《内科理论与实践》;20151213;345-349 * |
Also Published As
Publication number | Publication date |
---|---|
CN111187810B (zh) | 2020-09-29 |
CN111187810A (zh) | 2020-05-22 |
CN111575380A (zh) | 2020-08-25 |
CN109609635B (zh) | 2020-07-07 |
CN109609635A (zh) | 2019-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111575380B (zh) | 多基因检测用的探针库、杂交试剂盒和多基因检测的方法 | |
CN108004301B (zh) | 基因目标区域富集方法及建库试剂盒 | |
ES2688458T5 (es) | Recuento varietal de ácidos nucleicos para obtener información del número de copias genómicas | |
CN105518151B (zh) | 循环核酸肿瘤标志物的鉴别和用途 | |
CN104745679B (zh) | 一种无创检测egfr基因突变的方法及试剂盒 | |
CN107475375A (zh) | 一种用于与微卫星不稳定性相关微卫星位点进行杂交的dna探针库、检测方法和试剂盒 | |
WO2016040901A1 (en) | Identification and use of circulating nucleic acids | |
CN111712580B (zh) | 用于扩增双链dna的方法和试剂盒 | |
CN106834515A (zh) | 一种检测met基因14外显子突变的探针库、检测方法和试剂盒 | |
WO2016109939A1 (zh) | 一种富集循环肿瘤dna的方法和试剂 | |
CN106498082B (zh) | 卵巢癌易感基因变异文库构建方法 | |
EP3372686A1 (en) | Biomarker for detection of lung adenocarcinoma and use thereof | |
WO2021067484A1 (en) | Compositions and methods for analyzing cell-free dna in methylation partitioning assays | |
CN110343748A (zh) | 基于高通量靶向测序分析肿瘤突变负荷的方法 | |
BR112019013391A2 (pt) | Adaptador de ácido nucleico, e, método para detecção de uma mutação em uma molécula de dna circulante tumoral (ctdna) de fita dupla. | |
CN114480660A (zh) | 一种用于检测泛癌种的基因Panel、探针及应用 | |
CN111424087A (zh) | 基于二代测序的用于泛癌种检测或靶向用药的检测Panel、试剂盒及应用 | |
CN113736878A (zh) | 一种神经系统肿瘤检测的基因panel、试剂盒及其应用 | |
CN106754878B (zh) | 乳腺癌易感基因变异文库构建方法 | |
CN111690741A (zh) | 一种乳腺癌多基因筛选探针及其应用 | |
CN111154872A (zh) | 用于检测肺癌驱动性基因突变的探针及试剂盒 | |
CN106282361B (zh) | 用于捕获血液病相关基因的基因捕获试剂盒 | |
CN106337058B (zh) | Cryl1-ift88融合基因及其在原发性肝细胞癌诊断和治疗中的应用 | |
CN103797130A (zh) | 用于确定人体具有异常状态的系统和方法 | |
CN113817822B (zh) | 一种基于甲基化检测的肿瘤诊断试剂盒及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Probe library, hybridization kit and method for polygene detection Effective date of registration: 20221118 Granted publication date: 20210402 Pledgee: Shenzhen hi tech investment small loan Co.,Ltd. Pledgor: HAPLOX BIOTECHNOLOGY (SHENZHEN) Co.,Ltd. Registration number: Y2022980022405 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210402 Pledgee: Shenzhen hi tech investment small loan Co.,Ltd. Pledgor: HAPLOX BIOTECHNOLOGY (SHENZHEN) Co.,Ltd. Registration number: Y2022980022405 |